Mapp Biopharmaceutical

Today, Mapp Biopharmaceutical is a topic of interest and discussion in various areas. From politics to popular culture, Mapp Biopharmaceutical has captured the attention of people of all ages and backgrounds. Its impact and relevance have transcended borders, becoming a meeting point for debate and reflection. In this article, we will explore different facets of Mapp Biopharmaceutical, analyzing its influence on current society and its projection into the future. From its origins to its evolution over time, we will delve into a deep analysis that will allow us to understand the importance of Mapp Biopharmaceutical in our current reality.

Mapp Biopharmaceutical
Headquarters
San Diego Edit this on Wikidata
,
United States Edit this on Wikidata
Key people
Larry Zeitlin
(President)
Kevin Whaley
(CEO)[1]
ProductsBiopharmaceuticals
SubsidiariesLeafBio
Websitemappbio.com Edit this on Wikidata

Mapp Biopharmaceutical is an American pharmaceutical company founded in 2003 by Larry Zeitlin and Kevin Whaley.[2] Mapp Biopharmaceutical is based in San Diego, California. It is responsible for the research and development of ZMapp, a drug which is still[when?] under development and comprises three humanized monoclonal antibodies used as a treatment for Ebola virus disease.[3][4] The drug was first tested in humans during the 2014 West Africa Ebola virus outbreak.

The ZMapp drug is a result of the collaboration between Mapp Biopharmaceutical, LeafBio (the commercial arm of Mapp Biopharmaceutical),[5] Defyrus Inc. (Toronto), the U.S. government, and the Public Health Agency of Canada.[3] The antibody work came out of research projects funded by Defense Advanced Research Projects Agency (DARPA) more than a decade ago,[1] and years of funding by the Public Health Agency of Canada.[6] ZMapp is manufactured in the tobacco plant Nicotiana benthamiana in the bioproduction process known as "pharming" by Kentucky BioProcessing, a subsidiary of Reynolds American.[7][8][9]

References

  1. ^ a b Langreth, Robert; Chen, Caroline; Nash, James; Lauerman, John (August 4, 2014). "Ebola Drug Made From Tobacco Plant Saves U.S. Aid Workers". Bloomberg.
  2. ^ "BioPharm Company Tackles "Neglected" Infectious Diseases". Small Business Innovation Research. National Institutes of Health. January 31, 2020. Archived from the original on 20 October 2021. Retrieved 20 October 2021.
  3. ^ a b "ZMapp Information Sheet" (PDF). Mapp Biopharmaceutical. Archived from the original (PDF) on 2014-08-12.
  4. ^ "Mystery Ebola virus serum manufactured by San Diego firm". Los Angeles Times. August 4, 2014.
  5. ^ "LeafBio". Archived from the original on October 8, 2014. Retrieved August 12, 2014.
  6. ^ Helen Branswell for The Canadian Press. Aug. 5, 2014 Experimental Ebola drug based on research discoveries from Canada's national lab
  7. ^ Kroll, David (5 August 2014). "Ebola 'Secret Serum': Small Biopharma, The Army, And Big Tobacco". Forbes.
  8. ^ Parshley, Lois (8 August 2014). "ZMapp: The Experimental Ebola Treatment Explained". Popular Science.
  9. ^ Daniel, Fran (12 August 2014). "Ebola drug provided for two Americans by Reynolds American subsidiary". Winston-Salem Journal.